ERBB2 and cancer: Pertuzumab, a monoclonal antibody blocking HER2 homo- and hetero-dimerization that is approved for multiple cancer types25 alone did not affect pERK, but diminished slightly pHER3, pAKT, and pS6 (Fig. 2d and Supplementary Fig. 3).